Page last updated: 2024-11-07

deltorphin ii, ala(2)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

deltorphin II, Ala(2)-: isolated from skin extracts of frogs belonging to the genus Phyllomedusa; has affinity to opioid receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10033203
CHEMBL ID20226
CHEBI ID81498
MeSH IDM0167374
PubMed CID14840431
CHEMBL ID29078
MeSH IDM0167374
PubMed CID123795
MeSH IDM0167374

Synonyms (52)

Synonym
deltorphin ii
glycinamide, l-tyrosyl-d-alanyl-l-phenylalanyl-l-alpha-glutamyl-l-valyl-l-valyl-
deltorphin-ii
[d-ala2]-deltorphin ii, >=97% (hplc)
NCGC00167311-01
122752-16-3
CHEMBL20226 ,
chebi:81498 ,
deltorphin b
C18095
tyr-d-ala-phe-glu-val-val-gly-nh2
bdbm50000507
(s)-4-((s)-2-{(r)-2-[(s)-2-amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-3-phenyl-propionylamino)-4-{(s)-1-[(s)-1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propylcarbamoyl}-butyric acid
4-(2-{2-[2-amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-3-phenyl-propionylamino)-4-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propylcarbamoyl}-butyric acid (deltorphin b)
4-(2-{2-[2-amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-3-phenyl-propionylamino)-4-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propylcarbamoyl}-butyric acid
tyr-d-ala-phe-glu-val-val-glynh2
(s)-5-((s)-1-((s)-1-(2-amino-2-oxoethylamino)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-4-((s)-2-((r)-2-((s)-2-amino-3-(4-hydroxyphenyl)propanamido)propanamido)-3-phenylpropanamido)-5-oxopentanoic acid
[d-ala2]-deltorphin ii
CS-7608
AKOS024456444
mfcd00080072
tyr-d-ala-phe-glu-val-val-gly amide
[d-ala2]-deltorphin ii, >97%, powder
HY-P1013
deltorphin 2
Q27155423
deltorphin b(9ci)
h2n-tyr-d-ala-phe-glu-val-val-gly-nh2
(4s)-4-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
deltorphin 2(tfa)
BD110274
gtpl1615
(4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
delt-ii
(ala(2),glu(4))deltorphin
(ala(2))deltorphin ii
NCGC00163203-01
CHEMBL29078 ,
(s)-4-((s)-2-{(s)-2-[(s)-2-amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-3-phenyl-propionylamino)-4-{(s)-1-[(s)-1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propylcarbamoyl}-butyric acid
bdbm50009193
tyr-ala-phe-asp-val-val-gly
[3h]-deltorphin ii
gtpl3816
[3h]deltorphin ii
Q27077016
tyr-ala-phe-glu-val-val-gly-nh2
delt ii
deltorphin ii, ala(2)-
deltorphin, alanyl(2)-glutamyl(4)-
deltorphin, ala(2)-glu(4)-
2-ala-4-glu-deltorphin
(4s)-4-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The extent to which these effects can be attributed to changes in drug pharmacokinetics and bioavailability versus sensitivity of the neuronal circuits that mediate the affected behavioral functions, has not been established."( Chronic food restriction in rats augments the central rewarding effect of cocaine and the delta1 opioid agonist, DPDPE, but not the delta2 agonist, deltorphin-II.
Cabeza de Vaca, S; Carr, KD; Kim, GY, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
"8-fold rightward shift in the dose-response curve."( Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes.
Mattia, A; Mosberg, HI; Porreca, F; Vanderah, T, 1991
)
0.28
"3 nmol/rat of DADELT II and shifted the dose-response curve to the right, without decreasing the maximum effect."( Behavioural effects of deltorphins in rats.
Angelucci, F; Negri, L; Noviello, V, 1991
)
0.28
", the morphine dose-response curve shifted to the left and the ED50 value of morphine decreased."( Effects of a highly selective nonpeptide delta opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice.
Endoh, T; Misawa, M; Mori, T; Nagase, H; Suzuki, T; Tsuji, M, 1995
)
0.29
" At the dosage used, naltrindole occupied more than 98% of brain delta-opioid receptors without affecting mu-opioid-receptors."( Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
Improta, G; Lattanzi, R; Luchetti, F; Melchiorri, P; Negri, L; Potenza, RL, 1995
)
0.29
" injections of morphine or fentanyl, produced antinociceptive tolerance as shown by a significant rightward displacement of the agonist dose-response curves compared to controls."( Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky, EJ; Hruby, VJ; Inturrisi, CE; Porreca, F; Sadée, W, 1996
)
0.29
" The combinations of moxonidine-morphine and moxonidine-deltorphin II resulted in significant leftward shifts in the dose-response curves compared to those of each agonist administered separately."( Moxonidine, a selective imidazoline/alpha(2) adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice.
Fairbanks, CA; Kitto, KF; Posthumus, IJ; Stone, LS; Wilcox, GL, 2000
)
0.31
" None of the drugs affected the residual volume, micturition threshold pressure or bladder contraction pressure at any dosage examined."( Effects of opioid subtypes on detrusor overactivity in rats with cerebral infarction.
Ishiura, Y; Komatsu, K; Nagasaka, Y; Nakamura, Y; Namiki, M; Yokoyama, O, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency1.45810.000811.382244.6684AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.00040.00010.729810.0000AID749871
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki0.50000.00000.38458.6000AID749873
Delta-type opioid receptorHomo sapiens (human)Ki0.00130.00000.59789.9300AID749872
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.50000.00000.27869.0000AID749873
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)EC50 (µMol)0.00180.00110.40144.8000AID1700417
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)1.93900.00000.32639.4000AID1700416
Delta-type opioid receptorHomo sapiens (human)EC50 (µMol)0.00950.00000.43328.3000AID1700420; AID1700421
Mu-type opioid receptorMus musculus (house mouse)EC50 (µMol)0.00180.00020.03930.2030AID1700417
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km137.00000.01503.49967.0000AID679959
Solute carrier organic anion transporter family member 1A2Homo sapiens (human)Km330.00006.40007.42009.6000AID679954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID681151TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Gastroenterology, Feb, Volume: 120, Issue:2
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
AID1700417Agonist activity at MOR/DOR in wild-type C57BL6 mouse spinal cord membranes assessed as stimulation of [35S]-GTPgammaS binding measured after 60 mins by scintillation counting assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700416Agonist activity at EA-fragment beta-arrestin-tagged human MOR expressed in human U2OS cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 60 mins by beta-galactosidase based scintillation counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700426Agonist activity at EA-fragment beta-arrestin-tagged human MOR/DOR expressed in human U2OS cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 60 mins by beta-galactosidase based scintillation counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1254732Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by invert microscope analysis2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound.
AID749872Displacement of [3H]DPDPE from human delta opioid receptor expressed in mouse HN9.10 cell membranes2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Effect of anchoring 4-anilidopiperidines to opioid peptides.
AID1700431Agonist activity at DOR in MOR knock out C57BL6 mouse spinal cord membranes assessed as stimulation of [35S]-GTPgammaS binding measured after 60 mins by scintillation counting assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700429Agonist activity at EA-fragment beta-arrestin-tagged human MOR/DOR expressed in human U2OS cell membranes assessed as stimulation beta-arrestin recruitment at 10 uM after 60 mins by Pathhunter chemiluminescence assay relative to DAMGO2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700421Agonist activity at EA-fragment beta-arrestin-tagged human DOR expressed in human U2OS cell membranes assessed as stimulation beta-arrestin recruitment after 60 mins by Pathhunter chemiluminescence assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700422Agonist activity at EA-fragment beta-arrestin-tagged human MOR expressed in human U2OS cell membranes assessed as stimulation of [35S]-GTPgammaS binding at 10 uM after 60 mins by beta-galactosidase based scintillation counting method relative to DAMGO2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID681150TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID1700427Agonist activity at EA-fragment beta-arrestin-tagged human MOR/DOR expressed in human U2OS cell membranes assessed as stimulation of [35S]-GTPgammaS binding at 10 uM after 60 mins by beta-galactosidase based scintillation counting method relative to DAMGO2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID749876Inhibition of mu opioid receptor in guinea pig ileum/longitudinal muscle with myenteric plexus assessed as inhibition of electrically-stimulated muscle contraction2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Effect of anchoring 4-anilidopiperidines to opioid peptides.
AID1700423Agonist activity at EA-fragment beta-arrestin-tagged human MOR expressed in human U2OS cell membranes assessed as stimulation beta-arrestin recruitment at 10 uM after 60 mins by Pathhunter Chemiluminescence assay relative to DAMGO2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID679959TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Jul, Volume: 294, Issue:1
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier.
AID681149TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID1700428Agonist activity at EA-fragment beta-arrestin-tagged human MOR/DOR expressed in human U2OS cell membranes assessed as stimulation beta-arrestin recruitment after 60 mins by Pathhunter chemiluminescence assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700430Agonist activity at MOR in DOR knock out C57BL6 mouse spinal cord membranes assessed as stimulation of [35S]-GTPgammaS binding measured after 60 mins by scintillation counting assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID1700420Agonist activity at EA-fragment beta-arrestin-tagged human DOR expressed in human U2OS cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 60 mins by beta-galactosidase based scintillation counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.
AID680345TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Jul, Volume: 294, Issue:1
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier.
AID749873Displacement of [3H]DAMGO from rat mu opioid receptor expressed in mouse HN9.10 cell membranes2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Effect of anchoring 4-anilidopiperidines to opioid peptides.
AID679954TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Jul, Volume: 294, Issue:1
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier.
AID681135TP_TRANSPORTER: uptake in OATP-F-expressing CHO cells2002Molecular endocrinology (Baltimore, Md.), Oct, Volume: 16, Issue:10
Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.
AID749871Inhibition of delta opioid receptor in mouse vas deferens assessed as inhibition of electrically-stimulated muscle contraction2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Effect of anchoring 4-anilidopiperidines to opioid peptides.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID148991Inhibition of opioid receptor mu in guinea pig ileum (GPI)1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID149340Displacement of [3H]DSLET from delta opioid receptor in rat brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID149290Displacement of [3H]- DAGO from opioid receptor mu in rat brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID149339Displacement of [3H]- DPDPE from delta opioid receptor in rat brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID149204In vitro opioid receptor delta mediated mouse vas deferens (MVD) assay1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID149311Relative affinity for mu and delta opioid receptors in rat brain membrane1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID149310IC50 ratio is GPI/MVD1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and structure-activity relationships of deltorphin analogues.
AID1346361Human delta receptor (Opioid receptors)1992Life sciences, , Volume: 50, Issue:14
Synthesis and binding characteristics of the highly delta-specific new tritiated opioid peptide, [3H]deltorphin II.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346373Mouse delta receptor (Opioid receptors)1994Molecular pharmacology, Feb, Volume: 45, Issue:2
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (234)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.43)18.7374
1990's108 (46.15)18.2507
2000's97 (41.45)29.6817
2010's22 (9.40)24.3611
2020's6 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.45 (24.57)
Research Supply Index5.46 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other6 (100.00%)84.16%
Other233 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]